Axsome Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2017 Annual Meeting of Stockholders held on June 2, 2017. Axsome Therapeutics, Inc. is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Two proposals were submitted to stockholders. Of the 23,593,667 shares entitled to vote, 20,139,864 shares (approximately 85%) were represented, constituting a quorum.
- Proposal 1: Election of Class II Director
- Mark Saad was elected to serve until the 2020 annual meeting.
- Votes For: 15,164,072
- Votes Withheld: 1,179,290
- Broker Non-Votes: 3,796,502
- Proposal 2: Ratification of Independent Auditor
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Votes For: 20,136,517
- Votes Against: 633
- Votes Abstaining: 2,714
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For further details on the proposals, the filing references the definitive proxy statement on Schedule 14A filed on May 2, 2017.
Key Facts for Investor Verification
- Mark Saad was successfully elected as a Class II director.
- Ernst & Young LLP was overwhelmingly ratified as the independent auditor.
- Stockholder participation was high, with approximately 85% of entitled shares represented at the meeting.
- There were no broker non-votes regarding the auditor ratification proposal.